Professor Linardopoulos received his undergraduate degree in Chemistry at the Moscow State University and his graduate studies in the laboratory of Biotechnology at the National Hellenic Research Foundation and obtained his PhD in Cellular and Molecular Biology from the Faculty of Biology at University of Athens, Greece (1989–1993). During this period he was also awarded a Research Fellowship from the Arthritis and Rheumatism Council of Great Britain for studies at Guy's and St. Thomas' Hospitals, London (1990–1991).
In 1997 Professor Linardopoulos joined Onyx Pharmaceuticals, Richmond, CA, US, as an Associate Scientist and Project Leader. During his time at Onyx he determined the mechanisms of action for several small molecule inhibitors and guided the development of selected targets as therapeutic drugs.
Before his move to the USA, Professor Linardopoulos was awarded a Marie Curie Research Fellowship from the European Community and completed three years as a postdoctoral fellow at the Beatson Institute for Cancer Research, Glasgow in the laboratory of Genetics and Chemical Carcinogenesis (1993–1997).
Professor Linardopoulos directed the discovery and the development of a highly novel strategy for treatment of cancer using selective small molecule drugs. His focus was to further investigate cell cycle control and aneuploidy in order to identify and validate regulators as targets for cancer therapy.
Professor Spiros Linardopoulos joined the Breast Cancer Now Toby Robbins Research Centre and The Institute of Cancer Research, London as a Team Leader in September 2000. He has extensive experience in industrial and academic experimental cancer therapeutics and cancer cell biology, focused on drug development.
He is currently a member of several professional organisations, including the Marie Curie Fellowship Association, the Greek Chemical Society, and the Hellenic Biochemical and Biophysical Societies.
Professor Linardopoulos left the ICR in November 2020.